Confidence-Building Measure G

Vaccine production facilities

Anthrax vaccine manufacture

The BioReliance® Services business of Merck KGaA is primarily a Contract Testing Organisation, providing biosafety testing services for a wide range of global, biopharmaceutical companies.

The Glasgow facility also has a biomanufacturing facility. No products are manufactured for direct sale - only contract manufacturing for others. Typical products produced are (i) Cell Banks, (ii) Virus Seed Stocks and (iii) Viral Vectors.

Influenza: Manufacture of influenza vaccine based on WHO recommendations

Japanese Encephalitis Viral Vaccine

Valneva manufactures Japanese Encephalitis Viral vaccine (IXIARO®/JESPECT®) at its cGMP facilities in Livingston, Scotland. The site is licensed and operates under a Manufacturing Authorisation granted by the UK Medicines and Healthcare products Regulatory Agency (MHRA).

During 2020 Influenza vaccines and the adjuvant MF59 were manufactured at this facility: three distinct products for the market, Agrippal®, Fluad® and Fluad QIV®, (seasonal influenza strain presentations, the latter two formulated with MF59 adjuvant).

Northern Hemisphere Influenza vaccine: Cultivation of egg adapted influenza viruses. Four strains are incorporated within the vaccine (Quadrivalent), trade name Fluad QIV®. Three strains are incorporated within the vaccine (Trivalent), trade name Agrippal® or Fluad®.

Covid-19 Vaccine manufacture

Cobra Biologics, Keele is an MHRA licensed facility for the contract development and manufacture of Investigational Medicinal products; these being cell banks (microbial and mammalian), plasmid DNA and viral vector products for gene therapy uses.  Currently we are producing the COVID-19 vaccine AZD1222 bulk drug substance.